Testing Chiglitazar for fatty liver with diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes with an A1c level of 9.5% or lower.
- You have had a liver biopsy showing fatty liver with inflammation and scarring (stage 1b or more), or had one in the last 6 months.
- You have had a special ultrasound (FibroScan) that shows significant fat and stiffness in your liver.
- Your weight has been stable (not more than 10% change) for at least 3 months.
- You do not have other liver diseases, uncontrolled high blood pressure, or certain heart conditions within the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.
This study compares two versions of a combination medication (chiglitazar and metformin) to ensure they work the same way in the body. Researchers are recruiting healthy volunteers to help determine if the new formulation is equivalent to the standard version.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests if a medication called Chiglitazar (a type of insulin sensitizer) is safe and effective for people with cirrhosis caused by metabolic-associated fatty liver disease (MAFLD). It may help reduce liver scarring and improve metabolic health.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
This study tests a new drug called QL2401 to see if it can improve fatty liver disease (MASH) in people who also have diabetes, obesity, or related conditions. The drug is designed to reduce liver fat and slow scarring.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.